Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Conditions

Brain and Nervous System | Pediatrics

Phase Expanded Access

What is the purpose of this trial?

The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.

  • Trial with
    Oncoceutics, Inc.
  • Start Date
    07/10/2019
  • End Date
    02/27/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Regan Pulaski

  • Last Updated
    07/12/2019
  • Study HIC
    #2000024991